Gilbert PB - Search Results

1

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB. Huang Y, et al. Among authors: gilbert pb. Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23. Vaccine. 2015. PMID: 25454855 Free PMC article.

2

Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Gilbert PB, Self SG, Ashby MA. Gilbert PB, et al. Biometrics. 1998 Sep;54(3):799-814. Biometrics. 1998. PMID: 9750238

3

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network. Gilbert PB, et al. Vaccine. 2003 Jun 20;21(21-22):2933-47. doi: 10.1016/s0264-410x(03)00158-0. Vaccine. 2003. PMID: 12798637 Clinical Trial.

4

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

5

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Gilbert PB, Bosch RJ, Hudgens MG. Gilbert PB, et al. Biometrics. 2003 Sep;59(3):531-41. doi: 10.1111/1541-0420.00063. Biometrics. 2003. PMID: 14601754

6

Endpoints in vaccine trials.

Hudgens MG, Gilbert PB, Self SG. Hudgens MG, et al. Among authors: gilbert pb. Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra. Stat Methods Med Res. 2004. PMID: 15068256

7

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Lee D, et al. Among authors: gilbert pb. J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29. J Infect Dis. 2004. PMID: 15295694 Clinical Trial.

8

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

9

Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.

Gilbert PB, Sun Y. Gilbert PB, et al. Biostatistics. 2005 Jul;6(3):374-94. doi: 10.1093/biostatistics/kxi014. Epub 2005 Apr 14. Biostatistics. 2005. PMID: 15831584

10

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. Gilbert PB, et al. J Infect Dis. 2005 Sep 15;192(6):974-83. doi: 10.1086/432734. Epub 2005 Aug 12. J Infect Dis. 2005. PMID: 16107949 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

344 results

Search Page